Celldex Therapeutics, Inc. (CLDX) - Form 8-K Summary
Business Context and Reporting Period
Celldex Therapeutics, Inc., a biopharmaceutical company incorporated in Delaware, filed this Current Report on Form 8-K on May 7, 2026. The filing announces the release of financial results for the first quarter of 2026. The company's common stock trades on the Nasdaq Capital Market under the symbol CLDX.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the first quarter of 2026.
Material Changes
The filing does not contain specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
This 8-K filing does not include specific guidance, management commentary, risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for specific Q1 2026 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if there were any changes in capital structure or debt obligations during the quarter.